|Bid||109.35 x 900|
|Ask||109.51 x 800|
|Day's range||108.96 - 111.48|
|52-week range||86.88 - 154.24|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||22.20|
|Earnings date||04 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||155.44|
FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
Jazz Pharmaceuticals (NASDAQ: JAZZ) ended 2019 on a positive note, with shares up 20%. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some. Here's why Jazz sang off-key in Q1.
Jazz (JAZZ) delivered earnings and revenue surprises of -31.82% and -0.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. Jazz Pharmaceuticals (NASDAQ: JAZZ), a maker of sleep therapeutics and oncology drugs, has steadily grown annual revenue for more than a decade, announcing record annual revenue for 2019.
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...
It's been a sad week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ), who've watched their investment drop 14% to US$117 in...
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.